(RTTNews) - Eton Pharmaceuticals (ETON) announced positive results from bioequivalence study of ET-600, a patented oral solution of desmopressin under development for the treatment of central diabetes insipidus. In a bioequivalence study conducted in 75 human subjects, ET-600 showed pharmacokinetic equivalence to the FDA-approved reference product of the same active ingredient.
"We expect to submit the NDA shortly and have begun pre-launch commercial readiness activities in anticipation of a potential launch in the first quarter of 2026," said Sean Brynjelsen, CEO of Eton Pharmaceuticals.
For More Such Health News, visit rttnews.com.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
